TENX - Tenax stock surges ~65% on upcoming US patent linked to heart disease therapy

Tenax Therapeutics ( NASDAQ: TENX ) stock rose ~65% on Thursday after the company said a day ago that it received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a patent covering the use of IV levosimendan to treat pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).

The new claims were made in the patent application titled 'Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).'

The patent is expected to last until 2040.

"The protections this patent will provide are based on key discoveries from the HELP Study – the first study to demonstrate improved exercise tolerance in patients with this deadly disease," said Tenax CEO Chris Giordano.

Tenax noted that intravenous levosimendan was initially discovered and developed by Finland-based Orion and is approved in over 60 countries outside the U.S. for use in hospitalized patients with acutely decompensated heart failure.

Tenax has North American rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan.

Pulmonary hypertension a type of high blood pressure which affects the arteries in the lungs and the right side of the heart.

For further details see: